Yissum - Research Development Company of the Hebrew University

Using a sustained release delivery system of sirolimus for head and neck cancer treatment

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Using a sustained release delivery system of sirolimus for head and neck cancer treatment
Project ID : 7-2009-2314

Description of the technology

Once-daily, sustained-release Sirolimus delivery system

Categories

Oral Cavity, Oncology/Cancer, Sustained Release, Drug Delivery

Development Stage

Prototypes tested in vitro; pharmokinetic and pharmacodynamic testing in human volunteers planned

Patent Status

WO/2011/024168

Market

Patients diagnosed with dyspalsia/premalignant cancer lesions estimated as 1% of total population.
The vast majority of the annual 500,000 new squamous cell carcinomas of the head and neck (HNSCC) arise in the oral cavity as oral squamous cell carcinomas (OSCC); poor prognosis due to late diagnosis and failure to respond to available treatment options

Highlights

  • New sustained-release drug delivery system for preventing and treating oral cancer
  • Potentially malignant lesions in the oral cavity can be detected clinically without any invasive technology; there are no interventional advances that prevent cancer development in these lesions
  • Sirolimus (rapamycin), a macrocyclic lactone isolated from Streptomyces hygroscopicus, is one of the leading agents suggested for preventing and treating OSCC
  • Local sustained oral release of Sirolimus is an effective way of preventing the progression of oral lesions to carcinomas and of treating developed OSCC

Our Innovation

Local, sustained-release oral drug delivery system for early intervention to prevent potentially malignant - premalignant - lesions developing into OSCC and for the treatment of developed OSCC

Key Features

  • System resists harsh conditions in oral cavity
  • System maintains prolonged, local, oral drug delivery
  • Local drug delivery reduces undesired systemic side effects
  • Sustained local oral delivery minimizes the total required drug dose

Development Milestones

Seeking funding for ongoing research

The Opportunity

  • A medical device platform for drugs for the local treatment of oral cancer
  • Accelerated development time and regulatory process

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Rakefet Czerninski
,

Michael Friedman
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Drug delivery

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.